SBIR/STTR Research Award
Calcaftor, a CFTR stabilizer for Cystic Fibrosis treatment
Award amount
$224,550Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CALISTA THERAPEUTICS INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- E61VUUWBMTB7
- Solicitation number
- PA13-088
- Topic code
- NIDDK
Research abstract
DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled nebulizer dosing and an efficacy that is predictive of clinical effect. CF is a common inherited disease that causes thick mucus in the lungs, digestive tract and other tissues. CF life expectancy is just 37.4 years and currently there is no approved treatment for the majority of CF patients. CF is a major unmet medical need. Calcaftor acts by inhibiting a CFTR trafficking protein CAL that promotes loss of CFTR from the epithelial membrane and premature lysosomal digestion. This Phase I SBIR will undertake critical proof of concept studies into the safety and pharmacokinetic distribution of Calcaftor following pulmonar
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development of a selective PI3K-Akt-activating neurotrophic small molecule drug, MT-002, for the healing of corneal wounds in Neurotrophic Keratitis.
- An Automated Platform for High-throughput Network Electrophysiology
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
3 SBIR/STTR records share this UEI (2013–2021). Reported award amounts total $697,541. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services